ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

WESTON, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces newly published data demonstrating that stroke-related cardiovascular injury and dysfunction is induced by AIM2 inflammasome activation and pyroptosis in the heart, which can be blocked by Inflammasome ASC Inhibitor IC 100.

Read more at globenewswire.com